SLS BIO Co., Ltd (KOSDAQ:246250)
South Korea
· Delayed Price · Currency is KRW 1,969.00
+85.00 (4.51%)
At close: Jun 9, 2025
SLS BIO Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 |
| Operating Revenue | 5,472 | 8,371 | 9,023 | 10,752 | 6,214 | 5,821 |
| Other Revenue | - | - | - | -0 | 0 | -0 |
| Revenue | 5,472 | 8,371 | 9,023 | 10,752 | 6,214 | 5,821 |
| Revenue Growth (YoY) | -39.34% | -7.23% | -16.08% | 73.02% | 6.75% | - |
| Cost of Revenue | 6,175 | 6,102 | 5,912 | 6,542 | 4,851 | 4,379 |
| Gross Profit | -703.16 | 2,269 | 3,111 | 4,210 | 1,363 | 1,442 |
| Selling, General & Admin | 1,449 | 1,195 | 1,294 | 1,119 | 416.94 | 389.93 |
| Research & Development | 619.75 | 591 | 533.56 | 503.7 | 303.66 | 178.71 |
| Amortization of Goodwill & Intangibles | 25.11 | 24.04 | 20.08 | 17.53 | 20.64 | 18.72 |
| Operating Expenses | 2,187 | 1,981 | 2,080 | 1,786 | 840.46 | 686.58 |
| Operating Income | -2,890 | 287.62 | 1,031 | 2,424 | 522.53 | 755.62 |
| Interest Expense | -71.09 | -83.92 | -100.85 | -135.99 | -336.36 | -382.34 |
| Interest & Investment Income | 205.83 | 282.53 | 166.85 | 122.76 | 9.12 | 0.83 |
| Currency Exchange Gain (Loss) | -1.5 | -1.87 | -0.21 | -0.07 | - | - |
| Other Non Operating Income (Expenses) | -401 | -130.24 | -0.38 | 10.51 | -1.52 | -17.65 |
| EBT Excluding Unusual Items | -3,158 | 354.11 | 1,096 | 2,421 | 193.76 | 356.45 |
| Gain (Loss) on Sale of Investments | - | - | -39.06 | -236.35 | - | - |
| Gain (Loss) on Sale of Assets | 0.14 | -0 | -0.01 | 40.3 | 4 | - |
| Pretax Income | -3,158 | 354.11 | 1,057 | 2,225 | 197.76 | 356.45 |
| Income Tax Expense | 410.49 | 18.49 | -376.67 | -601.13 | -6.71 | 34.65 |
| Net Income | -3,568 | 335.63 | 1,434 | 2,826 | 204.47 | 321.8 |
| Net Income to Common | -3,568 | 335.63 | 1,434 | 2,826 | 204.47 | 321.8 |
| Net Income Growth | - | -76.60% | -49.26% | 1282.14% | -36.46% | - |
| Shares Outstanding (Basic) | 15 | 15 | 14 | 7 | 5 | 4 |
| Shares Outstanding (Diluted) | 15 | 15 | 14 | 7 | 5 | 4 |
| Shares Change (YoY) | -26.29% | 8.73% | 104.97% | 37.54% | 14.68% | - |
| EPS (Basic) | -236.91 | 21.96 | 102.00 | 412.00 | 41.00 | 74.00 |
| EPS (Diluted) | -236.91 | 21.96 | 102.00 | 412.00 | 41.00 | 74.00 |
| EPS Growth | - | -78.47% | -75.24% | 904.88% | -44.59% | - |
| Free Cash Flow | -2,358 | 269.92 | 2,162 | 3,315 | 97.66 | 845.88 |
| Free Cash Flow Per Share | -156.54 | 17.66 | 153.75 | 483.26 | 19.58 | 194.51 |
| Gross Margin | -12.85% | 27.10% | 34.48% | 39.16% | 21.93% | 24.77% |
| Operating Margin | -52.82% | 3.44% | 11.43% | 22.54% | 8.41% | 12.98% |
| Profit Margin | -65.21% | 4.01% | 15.89% | 26.28% | 3.29% | 5.53% |
| Free Cash Flow Margin | -43.09% | 3.22% | 23.96% | 30.83% | 1.57% | 14.53% |
| EBITDA | -1,593 | 1,624 | 2,309 | 3,727 | 1,139 | 1,416 |
| EBITDA Margin | -29.12% | 19.40% | 25.59% | 34.66% | 18.32% | 24.32% |
| D&A For EBITDA | 1,297 | 1,336 | 1,278 | 1,303 | 616.03 | 660.07 |
| EBIT | -2,890 | 287.62 | 1,031 | 2,424 | 522.53 | 755.62 |
| EBIT Margin | -52.82% | 3.44% | 11.43% | 22.54% | 8.41% | 12.98% |
| Effective Tax Rate | - | 5.22% | - | - | - | 9.72% |
| Advertising Expenses | - | - | - | - | - | 11.05 |
Source: S&P Capital IQ. Standard template. Financial Sources.